返回 
加入收藏
仙灵骨葆联合阿仑膦酸钠治疗骨质疏松症的临床观察
x
请在关注微信后，向客服人员索取文件
| 篇名： | 仙灵骨葆联合阿仑膦酸钠治疗骨质疏松症的临床观察 |
| TITLE： | |
| 摘要： | 目的：观察仙灵骨葆联合阿仑膦酸钠治疗骨质疏松症的临床疗效及安全性。方法：将112例骨质疏松症患者按随机数字表法分为治疗组和对照组，各56例。两组患者均给予补充碳酸钙、维生素D及调整生活方式等一般治疗。对照组患者口服阿仑膦酸钠片10 mg，qd；治疗组患者在对照组基础上加服仙灵骨葆胶囊1.5 g，bid。两组患者均治疗12周。观察两组患者治疗前后血清钙（S-Ca）、血清磷（S-P）、24 h尿钙（U-Ca）、碱性磷酸酶（ALP）、骨钙素、白介素（IL）-6及L2～4腰椎和股骨颈骨密度（BMD）水平，并比较临床疗效及毒副反应情况。结果：两组患者治疗后S-Ca、S-P水平比较，差异均无统计学意义（P＞0.05）；两组患者治疗后ALP、骨钙素、BMD水平显著升高，U-Ca、IL-6水平较治疗前显著降低，且治疗组优于对照组，差异有统计学意义（P＜0.05）。两组患者治疗后L2～4腰椎和股骨颈治疗组患者总有效率（92.86％）显著高于对照组（73.21％），差异有统计学意义（P＜0.05）。两组患者均未见明显毒副反应。结论：仙灵骨葆联合阿仑膦酸钠治疗骨质疏松症患者疗效显著，且安全性较好。 |
| ABSTRACT： | OBJECTIVE： To observe clinical efficacy and safety of Xianlinggubao combined with alendronate sodium in the treatment of osteoporosis. METHODS： 112 patients with osteoporosis were randomly divided into treatment group and control group with 56 cases in each group. Both group were given routine treatment as calcium carbonate， vitamin D and life style. Control group were given alendronate sodium 10 mg orally， qd； treatment group was additionally given Xianlinggubao capsule 1.5 g， bid， on the basis of control group. Both groups received 12 weeks of treatment. The levels of S-Ca， S-P， 24 h urinary calcium （U-Ca）， alkaline phosphatase （ALP）， osteocalcin， IL-6， bone mineral density （BMD） of L2-4 lumbar spine and femoral neck were observed in 2 groups before and after treatment. ?Clinical efficacy and toxic reaction were compared. RESULTS： There was no statistical significance in the levels of S-P and S-Ca between 2 groups after treatment （P＞0.05）； the level of ALP、osteocalcin、BMD increased in treatment group after treatment， the level of U-Ca and IL-6 decreased compared to before treatment， and the treatment group was better than the control group， with statistical significance （P＜0.05）. Total effective rate of treatment group （92.86％） was significantly higher than that of control group （73.21％）， with statistical significance （P＜0.05）. No obvious toxic side effects was found in 2 groups. CONCLUSIONS： Xianlinggubao combined with alendronate sodium shows significant therapeutic efficacy for patients with osteoporosis with good safety. |
| 期刊： | 2016年第27卷第17期 |
| 作者： | 侯晓升，姜文晓，庄建 |
| AUTHORS： | HOU Xiaosheng，JIANG Wenxiao，ZHUANG Jian |
| 关键字： | 骨质疏松症；仙灵骨葆胶囊；阿仑膦酸钠；疗效；安全性 |
| KEYWORDS： | Osteoporosis； Xianlinggubao capsule； Alendronate sodium； Clinical efficacy； Safety |
| 阅读数： | 517 次 |
| 本月下载数： | 2 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
